ABLi Therapeutics (ABLi) has officially launched.

ABLi Therapeutics (ABLi) 已正式成立。

The company is dedicated to developing therapies that target conditions caused by the activation of Abelson Tyrosine Kinases (c-Abl kinases), with Parkinson’s disease and related disorders as its primary focus.

公司致力于开发针对由阿贝森酪氨酸激酶（c-Abl激酶）激活引起的病症的疗法，主要专注于帕金森病及相关疾病。

Risvodetinib has shown encouraging results in clinical studies. In a recent placebo-controlled trial (NCT05424276), it was the first monotherapy to improve quality of life in patients with untreated Parkinson’s disease while also demonstrating a reduction in disease-related pathology.

Risvodetinib在临床研究中显示出令人鼓舞的结果。在最近的一项安慰剂对照试验（NCT05424276）中，它是首个在未治疗的帕金森病患者中改善生活质量的单药疗法，同时还显示出减少疾病相关病理的成效。

The treatment is taken orally once daily and has been designed to interfere with the mechanisms believed to drive disease progression. It is currently protected by intellectual property rights extending beyond 2036.

该疗法每日口服一次，旨在干预那些被认为是推动疾病进展的机制。目前，该疗法受到知识产权保护，保护期延长至2036年以后。

ABLi’s lead product candidate, risvodetinib (ABLi-148009), is being developed as a potential disease-modifying treatment. Unlike existing therapies that manage symptoms, risvodetinib aims to address the root causes of Parkinson’s disease.

ABLi公司的主要候选产品risvodetinib（ABLi-148009）正在被开发为一种潜在的疾病修饰治疗药物。与现有的仅管理症状的疗法不同，risvodetinib旨在解决帕金森病的根本原因。

The company has also established a portfolio of second-generation product candidates based on its proprietary RAMP™ drug development platform. This platform has produced a range of small-molecule inhibitors that are selective for non-receptor c-Abl kinases.

公司还基于其专有的RAMP™药物开发平台建立了一系列第二代候选产品组合。该平台已产生了一系列针对非受体c-Abl激酶的选择性小分子抑制剂。

These new compounds are reported to offer improved potency and safety compared to current commercially available options and are capable of reaching therapeutic levels in both the brain and peripheral tissues.

这些新化合物据报道比当前市面上可用的选项具有更高的效力和安全性，并且能够在大脑和周围组织中达到治疗水平。

ABLi is supported by a scientific advisory board comprising experts in Parkinson’s and related neurological conditions, guiding the company's efforts to bring innovative therapies to patients.

ABLi 得到了一个由帕金森病及相关神经系统疾病专家组成的科学顾问委员会的支持，该委员会指导公司为患者带来创新疗法的努力。

Source: globenewswire.com

来源：globenewswire.com